Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial

Cardiovasc Res. 2024 May 29;120(7):678-680. doi: 10.1093/cvr/cvae057.

¹ Abcentra, 1925 Century Park E #1700, Los Angeles, CA 90067, USA.
² Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA.
³ Department of Cardiology and Smidt Heart Institute, Oppenheimer Atherosclerosis Research Center, Cedars Sinai Medical Center, Los Angeles, CA, USA.
⁴ Caristo Diagnostics, Oxford, UK.
⁵ Radcliffe Department of Medicine, Division of Cardiovascular Medicine, Acute Multidisciplinary Imaging and Interventional Centre, University of Oxford, UK.
⁶ Department of Clinical Sciences Malmö, Lund University, Jan Waldenströms gata 35, 20502 Malmö, Sweden.
⁷ Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

No abstract available

Publication types